{"gene":"FIP1L1","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2003,"finding":"FIP1L1-PDGFRA fusion is a constitutively activated tyrosine kinase generated by an interstitial deletion on chromosome 4q12, which transforms hematopoietic cells; imatinib inhibits this kinase with an IC50 of 3.2 nM, and a T674I resistance mutation in the PDGFRA kinase domain confers imatinib resistance.","method":"Cell transformation assay, kinase inhibition assay, sequencing of resistance mutation in relapsed patient","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1-2 — constitutive kinase activity demonstrated in hematopoietic cell transformation, IC50 measured in vitro, resistance mutation identified in vivo; foundational paper with >1300 citations","pmids":["12660384"],"is_preprint":false},{"year":2003,"finding":"The T674I mutation in FIP1L1-PDGFRalpha (analogous to T315I in BCR-ABL) confers imatinib resistance, and PKC412 can overcome this resistance both in vitro and in a murine bone marrow transplant model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.","method":"Murine bone marrow transplant model, in vitro kinase inhibition, cell proliferation assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo murine model plus in vitro data, replicated gatekeeper mutation concept; >180 citations","pmids":["12781364"],"is_preprint":false},{"year":2006,"finding":"Constitutive activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane (JM) domain of PDGFRalpha between two conserved tryptophan residues; the FIP1L1 portion is completely dispensable for kinase activation, and the presence of an intact JM domain is autoinhibitory (overcomeable by enforced homodimerization).","method":"Deletion mutagenesis, in vitro kinase activity assays, in vivo transformation assays in Ba/F3 cells and murine models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional readout in vitro and in vivo, mechanistic dissection of activation domain; >100 citations","pmids":["16690743"],"is_preprint":false},{"year":2004,"finding":"Human Fip1 (hFip1) is an integral subunit of CPSF; it interacts with poly(A) polymerase (PAP) and has an arginine-rich RNA-binding motif that preferentially binds U-rich sequence elements on pre-mRNA; recombinant hFip1 is sufficient to stimulate PAP polyadenylation activity in a U-rich element-dependent manner; hFip1, CPSF160, and PAP form a ternary complex in vitro.","method":"Recombinant protein reconstitution, in vitro polyadenylation assay, co-immunoprecipitation, RNA-binding assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — reconstitution, in vitro enzymatic assay, and binding experiments in a single study; >200 citations","pmids":["14749727"],"is_preprint":false},{"year":1995,"finding":"Yeast Fip1 (ortholog of human FIP1L1) directly interacts with poly(A) polymerase (Pap1) in a 1:1 complex; it is an essential component of polyadenylation factor I (PF I); Fip1 tethers Pap1 to cleavage factor I (CF I) via direct interaction with RNA14; loss of Fip1 specifically abolishes polyadenylation (but not cleavage) in vitro.","method":"Two-hybrid assay, in vitro reconstitution (1:1 complex with Pap1), in vitro 3'-end processing assay with thermosensitive allele, co-immunoprecipitation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — reconstitution, genetic, and biochemical evidence in a single foundational study; >120 citations","pmids":["7736590"],"is_preprint":false},{"year":2001,"finding":"Yeast Fip1 has distinct functional domains: amino acids 80-105 bind Pap1 and inhibit its activity (by restricting RNA access to Pap1's C-terminal RNA-binding domain); amino acids 206-220 interact with Yth1 and are required for specific polyadenylation; the C-terminus of Fip1 is required to relieve Fip1-mediated repression of Pap1.","method":"Domain deletion mutagenesis, in vitro polyadenylation assay, binding assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with in vitro functional readout, multiple domains mapped; relevant yeast ortholog","pmids":["11238938"],"is_preprint":false},{"year":2008,"finding":"Crystal structure of yeast poly(A) polymerase in complex with Fip1 peptide (residues 80-105) at 2.6 Å resolution shows the Fip1 peptide binding to the outside surface of the C-terminal domain of Pap1; Fip1 is largely intrinsically disordered in solution; a lethal polymerase mutant (V498Y, C485R) that cannot bind Fip1 but retains full polymerase activity was engineered.","method":"X-ray crystallography, analytical ultracentrifugation, circular dichroism, mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis validation; yeast ortholog of FIP1L1","pmids":["18537269"],"is_preprint":false},{"year":2011,"finding":"Yeast Fip1 contains a flexible linker region in the middle of the protein; removal or replacement of this linker impairs polyadenylation efficiency; the linker provides a platform for critical interactions with other processing machinery components, and direct tethering of Pap1 to RNA rescues polyadenylation.","method":"In vitro polyadenylation assay, fusion protein complementation in vivo, genetic assays in yeast","journal":"RNA (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — in vitro polyadenylation plus in vivo genetic rescue; yeast ortholog of FIP1L1","pmids":["21282348"],"is_preprint":false},{"year":2014,"finding":"Mouse Fip1 is essential for embryonic stem cell (ESC) self-renewal and somatic cell reprogramming; Fip1 promotes stem cell maintenance by activating ESC-specific alternative polyadenylation (APA) profiles through Fip1-RNA interactions and proximity between APA sites; Fip1 expression and the APA program change during ESC differentiation and are restored during reprogramming.","method":"Genetic loss-of-function (Fip1 knockout/knockdown), RNA-seq/APA profiling, reprogramming assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — KO with defined cellular phenotype (loss of self-renewal), mechanism linked to APA regulation; >135 citations","pmids":["24596251"],"is_preprint":false},{"year":2020,"finding":"Crystal structure of human CPSF30 ZF4-ZF5 in complex with hFip1 residues 161-200 at 1.9 Å resolution shows one hFip1 molecule binding each of ZF4 and ZF5 with a conserved interaction mode; CPSF contains two copies of hFip1; ZF4 has higher affinity (Kd = 1.8 nM); two copies of PAP are recruited by the CPSF30-hFip1 complex, both supporting polyadenylation.","method":"X-ray crystallography, mutagenesis, fluorescence polarization binding assay, in vitro polyadenylation assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis and biochemical validation in a single study","pmids":["33122294"],"is_preprint":false},{"year":2021,"finding":"Yeast Fip1 anchors poly(A) polymerase Pap1 onto the CPF complex via interaction with zinc finger 4 of Yth1 (CPSF30 ortholog); NMR spectroscopy of selectively labeled Fip1 in a reconstituted 850-kDa CPF complex shows that the Fip1 IDR connecting Yth1- and Pap1-binding sites remains highly dynamic within the complex.","method":"Reconstitution of fully recombinant CPF, NMR spectroscopy, binding assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of megadalton complex with NMR structural validation; yeast ortholog","pmids":["34593603"],"is_preprint":false},{"year":2022,"finding":"Human Fip1 (hFip1) acts as a multivalent scaffold within CPSF: two copies of hFip1 each bind to ZF4 and ZF5 of CPSF30 (independently redundant for PAP recruitment); hFip1 interacts with CstF77 via a short motif in its N-terminal acidic region; CstF77 competitively inhibits CPSF-dependent PAP recruitment and polyadenylation.","method":"Crystal structures of hFip1-CPSF30 and hFip1-CstF77 complexes, in vitro polyadenylation assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 — two crystal structures plus functional polyadenylation assays; competitive inhibition mechanism established","pmids":["36073787"],"is_preprint":false},{"year":2007,"finding":"FIP1L1-PDGFRalpha activates multiple downstream signaling pathways in human hematopoietic progenitors: STAT5 and Akt activation require the FIP1L1 portion (aa 30-233), whereas p38 and ERK1/2 are activated by both full-length and truncated FIP1L1-PDGFRalpha; combined inhibition of PI3K and ERK1/2 significantly reverses FIP1L1-PDGFRalpha-induced colony formation; dominant-negative STAT5 partially inhibits colony formation.","method":"Retroviral transduction of human CD34+ progenitors, dominant-negative constructs, small-molecule pathway inhibitors, colony assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (DN-STAT5, PI3K inhibitor, ERK inhibitor, deletion mutants) in primary human cells","pmids":["17440089"],"is_preprint":false},{"year":2009,"finding":"FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells by more intensely activating MEK1/2 and p38 MAPK than TEL-PDGFRbeta; MEK1/2 and p38 inhibitors suppress this eosinophil development; FIP1L1-PDGFRalpha augments C/EBPalpha, GATA-1, and GATA-2 expression and suppresses PU.1 transcriptional activity via Ras.","method":"Murine hematopoietic progenitor transduction, kinase inhibitors, shRNA knockdown, luciferase reporter assays, bone marrow transplantation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches identifying pathway and transcription factor mechanism; in vivo and in vitro","pmids":["19147501"],"is_preprint":false},{"year":2009,"finding":"FIP1L1-PDGFRalpha and TEL-PDGFRbeta fusion proteins escape ubiquitination and proteasomal degradation (unlike wild-type activated receptors); Cbl-mediated ubiquitination is strongly reduced for the fusion proteins despite Cbl being phosphorylated; reducing SRC activity stabilizes FIP1L1-PDGFRalpha, and forced destabilization of the fusion reduces STAT5 activation and cell transformation.","method":"Pulse-chase protein stability assays, ubiquitination assays, destabilizing domain fusion constructs, patient leukocyte analysis","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 2 — multiple methods (pulse-chase, ubiquitination, engineered degron) with functional consequence; replicated in patient cells","pmids":["19644140"],"is_preprint":false},{"year":2012,"finding":"FIP1L1-PDGFRalpha activates JAK2, which is required for fusion kinase-induced proliferation and migration; JAK2 inhibition reduces STAT3 activation (not STAT5), and also reduces PI3K/Akt and NF-κB activity; JAK2 mediates IL-5-induced migration of FIP1L1-PDGFRalpha-positive cells.","method":"siRNA knockdown, JAK2 inhibitor AG490, signaling pathway analysis (Western blot) in EOL-1 and primary patient cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA and small molecule inhibitor with pathway readouts; single lab","pmids":["22523564"],"is_preprint":false},{"year":2012,"finding":"FIP1L1-PDGFRalpha activates NF-κB via PI3K; NF-κB activity is required for eosinophil differentiation marker expression (IL-5 receptor, eosinophil peroxidase) and colony formation from transduced human CD34+ hematopoietic progenitors; bortezomib and IκB kinase inhibitor block EOL-1 cell proliferation.","method":"Lentiviral transduction of human CD34+ cells, PI3K inhibitor, dominant-negative IκB, bortezomib treatment, expression microarrays","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 — multiple inhibitor approaches in primary human cells; pathway mechanistically defined","pmids":["22271894"],"is_preprint":false},{"year":2014,"finding":"SHP2 phosphatase binds directly to phospho-tyrosine 720 of FIP1L1-PDGFRalpha; this interaction is required for ERK signaling and cell transformation but not for STAT5 phosphorylation; mutation of Y720 inhibits myeloproliferation in transplanted mice and human CD34+ progenitor proliferation.","method":"Tyrosine mutagenesis, direct binding assay, SHP2 knockdown, in vivo murine bone marrow transplantation, human CD34+ progenitor assays","journal":"Molecular oncology","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding demonstrated, mutagenesis with in vivo and in vitro functional readout; multiple orthogonal methods","pmids":["24618081"],"is_preprint":false},{"year":2015,"finding":"The F604S mutation in FIP1L1-PDGFRalpha creates a binding site for the phosphatase domain of SHP-2, reducing CBL activation and SRC-dependent destabilization, thereby strongly stabilizing the fusion protein; SRC inhibition/knockdown mimics the stabilizing effect, establishing SRC as a regulator of FIP1L1-PDGFRalpha protein stability.","method":"Pulse-chase protein stability assay, SHP-2 binding assay, SRC inhibition/knockdown, mutagenesis screen","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — multiple complementary methods (pulse-chase, binding, SRC KD) establishing mechanism; single lab","pmids":["25761934"],"is_preprint":false},{"year":2014,"finding":"The FIP1 motif in FIP1L1-RARA plays a pivotal role in homodimerization and transcriptional repressor activity of the fusion; in FIP1L1-PDGFRalpha, the C-terminal PDGFRalpha portion alone can homodimerize and constitutively activate the kinase, making FIP1L1 dispensable for kinase activation but contributing to full IL-3 independence.","method":"Deletion mutant analysis, hematopoietic cell transformation assays in BAF-B03 cells","journal":"Annals of hematology","confidence":"Medium","confidence_rationale":"Tier 2 — deletion series with functional readout; consistent with PMID 16690743","pmids":["24763514"],"is_preprint":false},{"year":2006,"finding":"FIP1L1-PDGFRalpha cooperates with IL-5 to induce HES/CEL-like disease in mice; transplantation of FIP1L1-PDGFRalpha-positive HSCs alone produces a CML-like phenotype, but combined with IL-5 transgenic overexpression produces intense eosinophilia and multi-organ eosinophil infiltration, demonstrating that FIP1L1-PDGFRalpha is not sufficient alone and requires a second cytokine-driven event.","method":"Bone marrow transplantation in mice with IL-5 transgenic background; secondary transplantation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic epistasis experiment with clear mechanistic conclusion; >60 citations","pmids":["16418325"],"is_preprint":false},{"year":2008,"finding":"FIP1L1/PDGFRalpha synergizes with SCF/c-kit signaling to promote mast cell development; SCF stimulates greater migration and Akt activation in FIP1L1/PDGFRalpha-expressing mast cells, and anti-c-kit antibody reduces but does not abolish F/P-induced intestinal mast cell infiltration in vivo.","method":"Murine bone marrow transplantation, anti-c-kit antibody neutralization, in vitro mast cell cytokine-independent proliferation and migration assays, Akt signaling analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo neutralization plus in vitro signaling; shows synergism between two kinase pathways","pmids":["18539901"],"is_preprint":false},{"year":2006,"finding":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant T674I mutant, inducing apoptosis of EOL-1 cells at low nanomolar concentrations and blocking FIP1L1-PDGFRalpha phosphorylation by Western blot.","method":"Cell proliferation assay (Ba/F3 transformed cells, EOL-1), Western blot for kinase phosphorylation, apoptosis assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — direct kinase inhibition demonstrated with multiple cell models; >115 citations","pmids":["16645167"],"is_preprint":false},{"year":2007,"finding":"FIP1L1-PDGFRalpha induces eosinophil cell proliferation through induction of c-Myc expression via ERK and JNK signaling pathways; imatinib inhibits ERK and JNK phosphorylation and decreases c-Myc protein.","method":"MEK inhibitor (U0126), JNK inhibitor (SP600125), imatinib treatment; Western blot and proliferation assays in EOL-1 cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with specific small-molecule inhibitors; single lab","pmids":["18086564"],"is_preprint":false},{"year":2013,"finding":"FIP1L1/PDGFRalpha (F/P) upregulates oncostatin M (OSM) expression in a STAT5-dependent manner; OSM produced by neoplastic eosinophils stimulates stromal cell proliferation and CXCL12 production, which in turn induces neoplastic eosinophil migration—establishing a paracrine loop.","method":"Lentiviral F/P transduction, doxycycline-inducible F/P expression in Ba/F3, gene expression analysis, cytokine assays, chemotaxis assays, immunohistochemistry of patient bone marrow","journal":"Allergy","confidence":"Medium","confidence_rationale":"Tier 2 — inducible system plus patient tissue validation; pathway mechanism established","pmids":["23621172"],"is_preprint":false},{"year":2021,"finding":"FIP1 (human FIP1L1) binds to the proximal polyadenylation signal (pPAS) of NLRP3 mRNA via its arginine-rich domain and induces 3'UTR shortening of NLRP3, upregulating NLRP3 expression; FIP1 is upregulated by oxidative stress and this upregulation amplifies NLRP3-driven inflammation and fibrogenesis in kidney injury.","method":"RNA immunoprecipitation, shRNA knockdown, in vivo UUO/IRI kidney injury models, NLRP3 3'UTR reporter assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — direct RNA binding demonstrated (RIP), KD with in vivo phenotypic rescue; mechanism linked to APA regulation","pmids":["34011928"],"is_preprint":false},{"year":2005,"finding":"Human Fip1 (hFip1) interacts specifically with U-rich upstream elements of the HPV-16 early polyadenylation signal region, enhancing polyadenylation at the early poly(A) site; deletion of this U-rich element reduces early poly(A) site utilization and increases late mRNA production.","method":"RNA-protein binding assay, deletion mutagenesis, polyadenylation reporter assays","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — direct RNA-protein binding plus functional reporter assay; consistent with known hFip1 U-rich binding mechanism","pmids":["15767428"],"is_preprint":false}],"current_model":"FIP1L1 encodes two functionally distinct proteins: (1) as a core subunit of the CPSF mRNA 3'-end processing complex, hFip1 serves as a multivalent intrinsically disordered scaffold that binds U-rich RNA elements via its arginine-rich motif, recruits poly(A) polymerase (PAP) by tethering it to CPSF30 (ZF4/5) and stimulates PAP activity, interacts with CstF77 which competitively inhibits PAP recruitment, and regulates alternative polyadenylation essential for stem cell self-renewal; (2) when fused to PDGFRalpha by a cryptic 4q12 chromosomal deletion, the FIP1L1 portion is dispensable for constitutive kinase activation (which instead requires disruption of the PDGFRalpha juxtamembrane autoinhibitory domain), but the fusion oncoprotein—which escapes ubiquitination and degradation—drives myeloproliferation by activating STAT5, PI3K/Akt, ERK, p38, JAK2, NF-κB, and SHP2/ERK pathways, imposes eosinophil lineage commitment through MEK1/2-p38-C/EBPalpha/GATA axis, and is potently inhibited by imatinib (with T674I and D842V mutations conferring resistance)."},"narrative":{"teleology":[{"year":1995,"claim":"The founding discovery that yeast Fip1 is an essential polyadenylation factor that directly tethers poly(A) polymerase to the cleavage machinery established FIP1 as a core 3'-end processing component, resolving how PAP is recruited to pre-mRNA substrates.","evidence":"Two-hybrid, reconstitution of 1:1 Fip1–Pap1 complex, in vitro processing assay with thermosensitive allele in S. cerevisiae","pmids":["7736590"],"confidence":"High","gaps":["Human ortholog not yet characterized","RNA-binding specificity of Fip1 unknown","Structural basis of Fip1–Pap1 interaction unresolved"]},{"year":2001,"claim":"Domain mapping of yeast Fip1 revealed a dual-function architecture: one region binds and inhibits Pap1 while another contacts Yth1 (CPSF30 ortholog), explaining how Fip1 both represses nonspecific polyadenylation and enables site-specific poly(A) addition.","evidence":"Deletion mutagenesis with in vitro polyadenylation and binding assays in yeast","pmids":["11238938"],"confidence":"High","gaps":["How Fip1-mediated repression is relieved in the full complex unknown","No structural data on Fip1–Yth1 interface"]},{"year":2003,"claim":"Identification of the FIP1L1-PDGFRα fusion as a constitutively activated kinase caused by a 4q12 interstitial deletion established the molecular basis of imatinib-responsive hypereosinophilic syndrome, and the T674I gatekeeper mutation explained clinical imatinib resistance.","evidence":"Cell transformation assays, kinase inhibition (IC50 3.2 nM), sequencing of relapsed patient; confirmed in murine BM transplant model with PKC412 rescue","pmids":["12660384","12781364"],"confidence":"High","gaps":["Which portion of the fusion drives activation unclear","Downstream effector pathways not mapped","Mechanism of eosinophil lineage specificity unknown"]},{"year":2004,"claim":"Biochemical characterization of human hFip1 demonstrated it is a CPSF subunit with an arginine-rich motif that binds U-rich RNA and stimulates PAP activity, establishing conservation of the yeast Fip1 mechanism in mammals.","evidence":"Recombinant protein reconstitution, in vitro polyadenylation, co-IP, RNA-binding assay","pmids":["14749727"],"confidence":"High","gaps":["Stoichiometry of hFip1 within CPSF unknown","Structural basis of hFip1–CPSF30 interaction unresolved"]},{"year":2006,"claim":"Mutagenesis of FIP1L1-PDGFRα demonstrated that constitutive kinase activation requires disruption of the PDGFRα juxtamembrane autoinhibitory domain, while the FIP1L1 moiety is entirely dispensable, resolving a key question about the activation mechanism.","evidence":"Deletion mutagenesis, in vitro kinase assays, Ba/F3 transformation, murine models","pmids":["16690743"],"confidence":"High","gaps":["Role of FIP1L1 portion in signaling specificity or protein stability not addressed","Mechanism of eosinophil commitment still unknown"]},{"year":2007,"claim":"Mapping of FIP1L1-PDGFRα downstream signaling in human CD34+ progenitors revealed that STAT5 and Akt activation require the FIP1L1 N-terminal portion (aa 30–233) while ERK and p38 do not, showing the fusion partners differentially route oncogenic signals.","evidence":"Retroviral transduction of human CD34+ cells, dominant-negative STAT5, PI3K/ERK inhibitors, colony assays","pmids":["17440089"],"confidence":"High","gaps":["Molecular basis of FIP1L1 requirement for STAT5/Akt signaling unclear","In vivo validation in patient-derived cells limited"]},{"year":2008,"claim":"Crystal structure of the yeast Fip1 peptide–Pap1 complex revealed that Fip1 is intrinsically disordered and binds the outer surface of Pap1's C-terminal domain, providing the first atomic view of how this scaffold restricts polymerase activity.","evidence":"X-ray crystallography (2.6 Å), analytical ultracentrifugation, CD, lethal Pap1 mutants","pmids":["18537269"],"confidence":"High","gaps":["Full-length Fip1 structure unavailable","Human hFip1–PAP complex structure unresolved"]},{"year":2009,"claim":"Two studies established that FIP1L1-PDGFRα escapes Cbl-mediated ubiquitination (explaining its stability compared to wild-type receptors) and imposes eosinophil lineage commitment through MEK1/2–p38–C/EBPα/GATA signaling, connecting protein turnover and lineage specification to disease phenotype.","evidence":"Pulse-chase stability assays, ubiquitination assays, destabilizing domain fusions; murine progenitor transduction with kinase inhibitors and shRNA, BM transplantation","pmids":["19644140","19147501"],"confidence":"High","gaps":["How fusion evades Cbl ubiquitination structurally is unknown","Whether lineage commitment mechanism operates identically in human patients unclear"]},{"year":2014,"claim":"hFip1 was shown to be essential for embryonic stem cell self-renewal through regulation of ESC-specific alternative polyadenylation programs, establishing FIP1L1 as a master regulator of APA in cell fate decisions beyond constitutive 3'-end processing.","evidence":"Fip1 knockout/knockdown in mouse ESCs, RNA-seq/APA profiling, reprogramming assays","pmids":["24596251"],"confidence":"High","gaps":["Mechanism by which Fip1 selects specific APA sites over others not resolved","Whether hFip1 levels regulate APA in adult somatic tissues unknown"]},{"year":2014,"claim":"Identification of SHP2 binding to phospho-Y720 of FIP1L1-PDGFRα as required for ERK signaling and transformation but dispensable for STAT5 activation revealed a branchpoint separating two major oncogenic pathways downstream of the fusion.","evidence":"Y720 mutagenesis, direct binding assay, SHP2 knockdown, murine BM transplantation, human CD34+ assays","pmids":["24618081"],"confidence":"High","gaps":["Other phosphotyrosine docking sites on the fusion not systematically mapped","Whether SHP2 inhibitors have therapeutic utility not tested"]},{"year":2020,"claim":"Crystal structures of hFip1 bound to CPSF30 ZF4 and ZF5 revealed that CPSF contains two copies of hFip1, each recruiting one PAP molecule, establishing the stoichiometric and structural basis for multivalent PAP recruitment within the mammalian polyadenylation machinery.","evidence":"X-ray crystallography (1.9 Å), fluorescence polarization binding (Kd 1.8 nM for ZF4), mutagenesis, in vitro polyadenylation","pmids":["33122294"],"confidence":"High","gaps":["Functional consequence of having two PAP copies versus one not determined","Full CPSF holoenzyme structure with hFip1 not available"]},{"year":2022,"claim":"Discovery that CstF77 binds hFip1's N-terminal region and competitively inhibits PAP recruitment revealed a built-in regulatory switch within CPSF that controls the transition from cleavage to polyadenylation.","evidence":"Crystal structures of hFip1–CstF77 complex, in vitro polyadenylation assays showing competitive inhibition","pmids":["36073787"],"confidence":"High","gaps":["How CstF77 release is triggered during the cleavage-to-polyadenylation transition in vivo unknown","Regulation of this switch in APA site selection not tested"]},{"year":null,"claim":"The structural basis of hFip1's RNA-binding specificity for U-rich elements, the mechanism by which hFip1 selects between proximal and distal polyadenylation sites in vivo, and whether the two copies of hFip1 within CPSF serve functionally distinct roles remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of hFip1 arginine-rich domain bound to RNA","No genome-wide dissection of individual hFip1 copy contributions","How hFip1-driven APA interfaces with transcription elongation rate is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[3,4,25,26]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,9,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,11]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,8]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[3,4,5,8,9,11,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,12,13,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,2,12,13,14]}],"complexes":["CPSF (cleavage and polyadenylation specificity factor)"],"partners":["CPSF1","CPSF4","PAPOLA","CSTF3","PDGFRA","SHP2","CBL"],"other_free_text":[]},"mechanistic_narrative":"FIP1L1 encodes hFip1, an intrinsically disordered scaffold subunit of the cleavage and polyadenylation specificity factor (CPSF) complex that is essential for mRNA 3'-end processing and alternative polyadenylation (APA). Two copies of hFip1 bind CPSF30 zinc fingers ZF4 and ZF5 to recruit poly(A) polymerase (PAP) via its arginine-rich RNA-binding motif that preferentially recognizes U-rich elements, while CstF77 competitively inhibits PAP recruitment through a distinct hFip1 N-terminal interaction, providing a regulatory switch for polyadenylation [PMID:14749727, PMID:33122294, PMID:36073787]. hFip1-directed APA is required for embryonic stem cell self-renewal and somatic cell reprogramming, and regulates inflammatory gene expression through 3'UTR shortening of targets such as NLRP3 [PMID:24596251, PMID:34011928]. A cryptic interstitial deletion on chromosome 4q12 fuses FIP1L1 to PDGFRα, generating a constitutively active tyrosine kinase—driven by loss of the PDGFRα juxtamembrane autoinhibitory domain rather than by the FIP1L1 moiety—that activates STAT5, PI3K/Akt, ERK, p38, JAK2, NF-κB, and SHP2 pathways to cause imatinib-sensitive myeloproliferative neoplasm with eosinophilia [PMID:12660384, PMID:16690743, PMID:17440089, PMID:24618081]."},"prefetch_data":{"uniprot":{"accession":"Q6UN15","full_name":"Pre-mRNA 3'-end-processing factor FIP1","aliases":["FIP1-like 1 protein","Factor interacting with PAP","Rearranged in hypereosinophilia"],"length_aa":594,"mass_kda":66.5,"function":"Component of the cleavage and polyadenylation specificity factor (CPSF) complex that plays a key role in pre-mRNA 3'-end formation, recognizing the AAUAAA signal sequence and interacting with poly(A) polymerase and other factors to bring about cleavage and poly(A) addition. FIP1L1 contributes to poly(A) site recognition and stimulates poly(A) addition. Binds to U-rich RNA sequence elements surrounding the poly(A) site. May act to tether poly(A) polymerase to the CPSF complex","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q6UN15/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/FIP1L1","classification":"Common Essential","n_dependent_lines":1141,"n_total_lines":1208,"dependency_fraction":0.9445364238410596},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"RBM14","stoichiometry":0.2},{"gene":"SNRPA","stoichiometry":0.2},{"gene":"SNRPC","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/FIP1L1","total_profiled":1310},"omim":[{"mim_id":"612839","title":"TET METHYLCYTOSINE DIOXYGENASE 2; TET2","url":"https://www.omim.org/entry/612839"},{"mim_id":"607686","title":"FIP1-LIKE 1; FIP1L1","url":"https://www.omim.org/entry/607686"},{"mim_id":"607685","title":"HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES","url":"https://www.omim.org/entry/607685"},{"mim_id":"602388","title":"SYMPLEKIN; SYMPK","url":"https://www.omim.org/entry/602388"},{"mim_id":"173490","title":"PLATELET-DERIVED GROWTH FACTOR RECEPTOR, ALPHA; PDGFRA","url":"https://www.omim.org/entry/173490"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FIP1L1"},"hgnc":{"alias_symbol":["DKFZp586K0717","FIP1","hFip1"],"prev_symbol":[]},"alphafold":{"accession":"Q6UN15","domains":[{"cath_id":"1.10.287","chopping":"148-197","consensus_level":"medium","plddt":79.5044,"start":148,"end":197}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6UN15","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6UN15-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6UN15-F1-predicted_aligned_error_v6.png","plddt_mean":55.09},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FIP1L1","jax_strain_url":"https://www.jax.org/strain/search?query=FIP1L1"},"sequence":{"accession":"Q6UN15","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6UN15.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6UN15/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6UN15"}},"corpus_meta":[{"pmid":"12660384","id":"PMC_12660384","title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","date":"2003","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12660384","citation_count":1311,"is_preprint":false},{"pmid":"12842979","id":"PMC_12842979","title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12842979","citation_count":298,"is_preprint":false},{"pmid":"15284118","id":"PMC_15284118","title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15284118","citation_count":246,"is_preprint":false},{"pmid":"15070659","id":"PMC_15070659","title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15070659","citation_count":212,"is_preprint":false},{"pmid":"14749727","id":"PMC_14749727","title":"Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14749727","citation_count":209,"is_preprint":false},{"pmid":"19262599","id":"PMC_19262599","title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.","date":"2009","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/19262599","citation_count":203,"is_preprint":false},{"pmid":"12781364","id":"PMC_12781364","title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.","date":"2003","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12781364","citation_count":186,"is_preprint":false},{"pmid":"17299092","id":"PMC_17299092","title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17299092","citation_count":159,"is_preprint":false},{"pmid":"17666373","id":"PMC_17666373","title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.","date":"2007","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/17666373","citation_count":156,"is_preprint":false},{"pmid":"24596251","id":"PMC_24596251","title":"Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal.","date":"2014","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/24596251","citation_count":139,"is_preprint":false},{"pmid":"14973504","id":"PMC_14973504","title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.","date":"2004","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/14973504","citation_count":133,"is_preprint":false},{"pmid":"17377585","id":"PMC_17377585","title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17377585","citation_count":125,"is_preprint":false},{"pmid":"7736590","id":"PMC_7736590","title":"The FIP1 gene encodes a component of a yeast pre-mRNA polyadenylation factor that directly interacts with poly(A) polymerase.","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7736590","citation_count":123,"is_preprint":false},{"pmid":"18843283","id":"PMC_18843283","title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18843283","citation_count":122,"is_preprint":false},{"pmid":"16645167","id":"PMC_16645167","title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16645167","citation_count":119,"is_preprint":false},{"pmid":"16406016","id":"PMC_16406016","title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.","date":"2006","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/16406016","citation_count":107,"is_preprint":false},{"pmid":"16690743","id":"PMC_16690743","title":"Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16690743","citation_count":101,"is_preprint":false},{"pmid":"19212337","id":"PMC_19212337","title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.","date":"2009","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/19212337","citation_count":99,"is_preprint":false},{"pmid":"16030188","id":"PMC_16030188","title":"The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16030188","citation_count":99,"is_preprint":false},{"pmid":"14630792","id":"PMC_14630792","title":"The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14630792","citation_count":85,"is_preprint":false},{"pmid":"17628645","id":"PMC_17628645","title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.","date":"2007","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17628645","citation_count":81,"is_preprint":false},{"pmid":"18307562","id":"PMC_18307562","title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.","date":"2008","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/18307562","citation_count":67,"is_preprint":false},{"pmid":"15767428","id":"PMC_15767428","title":"A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/15767428","citation_count":62,"is_preprint":false},{"pmid":"17440089","id":"PMC_17440089","title":"Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17440089","citation_count":62,"is_preprint":false},{"pmid":"16418325","id":"PMC_16418325","title":"The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16418325","citation_count":62,"is_preprint":false},{"pmid":"16409293","id":"PMC_16409293","title":"Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.","date":"2006","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/16409293","citation_count":60,"is_preprint":false},{"pmid":"14676627","id":"PMC_14676627","title":"The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.","date":"2004","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14676627","citation_count":57,"is_preprint":false},{"pmid":"11238938","id":"PMC_11238938","title":"Fip1 regulates the activity of Poly(A) polymerase through multiple interactions.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11238938","citation_count":57,"is_preprint":false},{"pmid":"32720700","id":"PMC_32720700","title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.","date":"2020","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/32720700","citation_count":55,"is_preprint":false},{"pmid":"15921374","id":"PMC_15921374","title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.","date":"2005","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/15921374","citation_count":51,"is_preprint":false},{"pmid":"16282318","id":"PMC_16282318","title":"An Arabidopsis Fip1 homolog interacts with RNA and provides conceptual links with a number of other polyadenylation factor subunits.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16282318","citation_count":49,"is_preprint":false},{"pmid":"22447844","id":"PMC_22447844","title":"Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22447844","citation_count":47,"is_preprint":false},{"pmid":"22271894","id":"PMC_22271894","title":"ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.","date":"2012","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/22271894","citation_count":43,"is_preprint":false},{"pmid":"19644140","id":"PMC_19644140","title":"The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.","date":"2009","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/19644140","citation_count":42,"is_preprint":false},{"pmid":"15257945","id":"PMC_15257945","title":"FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.","date":"2004","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/15257945","citation_count":41,"is_preprint":false},{"pmid":"19144405","id":"PMC_19144405","title":"Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.","date":"2009","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/19144405","citation_count":40,"is_preprint":false},{"pmid":"31111599","id":"PMC_31111599","title":"The polyadenylation factor FIP1 is important for plant development and root responses to abiotic stresses.","date":"2019","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31111599","citation_count":38,"is_preprint":false},{"pmid":"20610657","id":"PMC_20610657","title":"FIP1/RCP binding to Golgin-97 regulates retrograde transport from recycling endosomes to the trans-Golgi network.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20610657","citation_count":38,"is_preprint":false},{"pmid":"34047477","id":"PMC_34047477","title":"Glioma glycolipid metabolism: MSI2-SNORD12B-FIP1L1-ZBTB4 feedback loop as a potential treatment target.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34047477","citation_count":36,"is_preprint":false},{"pmid":"17495975","id":"PMC_17495975","title":"The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17495975","citation_count":36,"is_preprint":false},{"pmid":"16682077","id":"PMC_16682077","title":"Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.","date":"2006","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/16682077","citation_count":35,"is_preprint":false},{"pmid":"18987650","id":"PMC_18987650","title":"Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18987650","citation_count":34,"is_preprint":false},{"pmid":"24407160","id":"PMC_24407160","title":"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.","date":"2014","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24407160","citation_count":34,"is_preprint":false},{"pmid":"29780398","id":"PMC_29780398","title":"FIP1 Plays an Important Role in Nitrate Signaling and Regulates CIPK8 and CIPK23 Expression in Arabidopsis.","date":"2018","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/29780398","citation_count":32,"is_preprint":false},{"pmid":"16344672","id":"PMC_16344672","title":"Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.","date":"2005","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16344672","citation_count":32,"is_preprint":false},{"pmid":"16920206","id":"PMC_16920206","title":"The Rab11-FIP1/RCP gene codes for multiple protein transcripts related to the plasma membrane recycling system.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16920206","citation_count":30,"is_preprint":false},{"pmid":"16406018","id":"PMC_16406018","title":"Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.","date":"2006","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/16406018","citation_count":29,"is_preprint":false},{"pmid":"34011928","id":"PMC_34011928","title":"Alternative polyadenylation trans-factor FIP1 exacerbates UUO/IRI-induced kidney injury and contributes to AKI-CKD transition via ROS-NLRP3 axis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34011928","citation_count":28,"is_preprint":false},{"pmid":"16387954","id":"PMC_16387954","title":"Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity.","date":"2006","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/16387954","citation_count":28,"is_preprint":false},{"pmid":"18537269","id":"PMC_18537269","title":"Structure of yeast poly(A) polymerase in complex with a peptide from Fip1, an intrinsically disordered protein.","date":"2008","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18537269","citation_count":27,"is_preprint":false},{"pmid":"22523564","id":"PMC_22523564","title":"Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22523564","citation_count":27,"is_preprint":false},{"pmid":"19147501","id":"PMC_19147501","title":"FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19147501","citation_count":27,"is_preprint":false},{"pmid":"18987651","id":"PMC_18987651","title":"The molecular anatomy of the FIP1L1-PDGFRA fusion gene.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18987651","citation_count":25,"is_preprint":false},{"pmid":"27120808","id":"PMC_27120808","title":"Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27120808","citation_count":25,"is_preprint":false},{"pmid":"24040321","id":"PMC_24040321","title":"The rab11 effector protein FIP1 regulates adiponectin trafficking and secretion.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24040321","citation_count":24,"is_preprint":false},{"pmid":"18619723","id":"PMC_18619723","title":"Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18619723","citation_count":23,"is_preprint":false},{"pmid":"33403789","id":"PMC_33403789","title":"Rab11-FIP1 mediates epithelial-mesenchymal transition and invasion in esophageal cancer.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33403789","citation_count":21,"is_preprint":false},{"pmid":"28223489","id":"PMC_28223489","title":"Structural basis of jasmonate-amido synthetase FIN219 in complex with glutathione S-transferase FIP1 during the JA signal regulation.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28223489","citation_count":21,"is_preprint":false},{"pmid":"17914408","id":"PMC_17914408","title":"The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17914408","citation_count":21,"is_preprint":false},{"pmid":"19210352","id":"PMC_19210352","title":"A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.","date":"2009","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/19210352","citation_count":20,"is_preprint":false},{"pmid":"24472312","id":"PMC_24472312","title":"Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24472312","citation_count":20,"is_preprint":false},{"pmid":"24763514","id":"PMC_24763514","title":"FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia.","date":"2014","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24763514","citation_count":19,"is_preprint":false},{"pmid":"16502585","id":"PMC_16502585","title":"Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia.","date":"2006","source":"Methods in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16502585","citation_count":19,"is_preprint":false},{"pmid":"21282348","id":"PMC_21282348","title":"A flexible linker region in Fip1 is needed for efficient mRNA polyadenylation.","date":"2011","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21282348","citation_count":17,"is_preprint":false},{"pmid":"19728396","id":"PMC_19728396","title":"Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.","date":"2010","source":"Hematological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19728396","citation_count":17,"is_preprint":false},{"pmid":"34593603","id":"PMC_34593603","title":"Dynamics in Fip1 regulate eukaryotic mRNA 3' end processing.","date":"2021","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/34593603","citation_count":16,"is_preprint":false},{"pmid":"19671059","id":"PMC_19671059","title":"Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.","date":"2009","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19671059","citation_count":16,"is_preprint":false},{"pmid":"34304603","id":"PMC_34304603","title":"FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.","date":"2021","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/34304603","citation_count":16,"is_preprint":false},{"pmid":"24618081","id":"PMC_24618081","title":"The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24618081","citation_count":16,"is_preprint":false},{"pmid":"19187542","id":"PMC_19187542","title":"FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia.","date":"2009","source":"BMC blood disorders","url":"https://pubmed.ncbi.nlm.nih.gov/19187542","citation_count":16,"is_preprint":false},{"pmid":"17215855","id":"PMC_17215855","title":"FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17215855","citation_count":15,"is_preprint":false},{"pmid":"18028420","id":"PMC_18028420","title":"Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.","date":"2007","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/18028420","citation_count":15,"is_preprint":false},{"pmid":"24669761","id":"PMC_24669761","title":"Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.","date":"2014","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24669761","citation_count":15,"is_preprint":false},{"pmid":"20523072","id":"PMC_20523072","title":"FIP1L1/PDGFR alpha-associated systemic mastocytosis.","date":"2010","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20523072","citation_count":14,"is_preprint":false},{"pmid":"33122294","id":"PMC_33122294","title":"Molecular mechanism for the interaction between human CPSF30 and hFip1.","date":"2020","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/33122294","citation_count":13,"is_preprint":false},{"pmid":"37035898","id":"PMC_37035898","title":"The Arabidopsis pre-mRNA 3' end processing related protein FIP1 promotes seed dormancy via the DOG1 and ABA pathways.","date":"2023","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37035898","citation_count":13,"is_preprint":false},{"pmid":"18539901","id":"PMC_18539901","title":"FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18539901","citation_count":13,"is_preprint":false},{"pmid":"36073787","id":"PMC_36073787","title":"Fip1 is a multivalent interaction scaffold for processing factors in human mRNA 3' end biogenesis.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36073787","citation_count":12,"is_preprint":false},{"pmid":"25761934","id":"PMC_25761934","title":"F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25761934","citation_count":12,"is_preprint":false},{"pmid":"28396819","id":"PMC_28396819","title":"Rab11-FIP1 phosphorylation by MARK2 regulates polarity in MDCK cells.","date":"2017","source":"Cellular logistics","url":"https://pubmed.ncbi.nlm.nih.gov/28396819","citation_count":12,"is_preprint":false},{"pmid":"24009732","id":"PMC_24009732","title":"The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24009732","citation_count":11,"is_preprint":false},{"pmid":"16513534","id":"PMC_16513534","title":"Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy.","date":"2006","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16513534","citation_count":11,"is_preprint":false},{"pmid":"25431951","id":"PMC_25431951","title":"Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25431951","citation_count":10,"is_preprint":false},{"pmid":"17591942","id":"PMC_17591942","title":"A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint.","date":"2007","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/17591942","citation_count":10,"is_preprint":false},{"pmid":"23621172","id":"PMC_23621172","title":"Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.","date":"2013","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/23621172","citation_count":10,"is_preprint":false},{"pmid":"25923837","id":"PMC_25923837","title":"Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia.","date":"2015","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25923837","citation_count":10,"is_preprint":false},{"pmid":"34638806","id":"PMC_34638806","title":"Rab11-FIP1 and Rab11-FIP5 Regulate pIgR/pIgA Transcytosis through TRIM21-Mediated Polyubiquitination.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34638806","citation_count":9,"is_preprint":false},{"pmid":"24460680","id":"PMC_24460680","title":"Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.","date":"2014","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24460680","citation_count":9,"is_preprint":false},{"pmid":"17701174","id":"PMC_17701174","title":"A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12.","date":"2007","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17701174","citation_count":9,"is_preprint":false},{"pmid":"19338765","id":"PMC_19338765","title":"The FIP-1 like polyadenylation factor in trypanosomes and the structural basis for its interaction with CPSF30.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19338765","citation_count":8,"is_preprint":false},{"pmid":"21302907","id":"PMC_21302907","title":"Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia.","date":"2011","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/21302907","citation_count":8,"is_preprint":false},{"pmid":"19118897","id":"PMC_19118897","title":"Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations.","date":"2008","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/19118897","citation_count":8,"is_preprint":false},{"pmid":"23232855","id":"PMC_23232855","title":"A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.","date":"2013","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23232855","citation_count":8,"is_preprint":false},{"pmid":"24486648","id":"PMC_24486648","title":"Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.","date":"2014","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24486648","citation_count":7,"is_preprint":false},{"pmid":"18086564","id":"PMC_18086564","title":"Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18086564","citation_count":7,"is_preprint":false},{"pmid":"18706197","id":"PMC_18706197","title":"FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.","date":"2008","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18706197","citation_count":7,"is_preprint":false},{"pmid":"17988989","id":"PMC_17988989","title":"Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.","date":"2007","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17988989","citation_count":7,"is_preprint":false},{"pmid":"29025601","id":"PMC_29025601","title":"A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.","date":"2017","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29025601","citation_count":7,"is_preprint":false},{"pmid":"34249738","id":"PMC_34249738","title":"Myeloid Sarcoma Type of Acute Promyelocytic Leukemia With a Cryptic Insertion of RARA Into FIP1L1: The Clinical Utility of NGS and Bioinformatic Analyses.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34249738","citation_count":7,"is_preprint":false},{"pmid":"26457233","id":"PMC_26457233","title":"Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing.","date":"2015","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26457233","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53665,"output_tokens":6849,"usd":0.131865},"stage2":{"model":"claude-opus-4-6","input_tokens":10498,"output_tokens":3370,"usd":0.20511},"total_usd":0.336975,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"FIP1L1-PDGFRA fusion is a constitutively activated tyrosine kinase generated by an interstitial deletion on chromosome 4q12, which transforms hematopoietic cells; imatinib inhibits this kinase with an IC50 of 3.2 nM, and a T674I resistance mutation in the PDGFRA kinase domain confers imatinib resistance.\",\n      \"method\": \"Cell transformation assay, kinase inhibition assay, sequencing of resistance mutation in relapsed patient\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — constitutive kinase activity demonstrated in hematopoietic cell transformation, IC50 measured in vitro, resistance mutation identified in vivo; foundational paper with >1300 citations\",\n      \"pmids\": [\"12660384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The T674I mutation in FIP1L1-PDGFRalpha (analogous to T315I in BCR-ABL) confers imatinib resistance, and PKC412 can overcome this resistance both in vitro and in a murine bone marrow transplant model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.\",\n      \"method\": \"Murine bone marrow transplant model, in vitro kinase inhibition, cell proliferation assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo murine model plus in vitro data, replicated gatekeeper mutation concept; >180 citations\",\n      \"pmids\": [\"12781364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Constitutive activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane (JM) domain of PDGFRalpha between two conserved tryptophan residues; the FIP1L1 portion is completely dispensable for kinase activation, and the presence of an intact JM domain is autoinhibitory (overcomeable by enforced homodimerization).\",\n      \"method\": \"Deletion mutagenesis, in vitro kinase activity assays, in vivo transformation assays in Ba/F3 cells and murine models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional readout in vitro and in vivo, mechanistic dissection of activation domain; >100 citations\",\n      \"pmids\": [\"16690743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Human Fip1 (hFip1) is an integral subunit of CPSF; it interacts with poly(A) polymerase (PAP) and has an arginine-rich RNA-binding motif that preferentially binds U-rich sequence elements on pre-mRNA; recombinant hFip1 is sufficient to stimulate PAP polyadenylation activity in a U-rich element-dependent manner; hFip1, CPSF160, and PAP form a ternary complex in vitro.\",\n      \"method\": \"Recombinant protein reconstitution, in vitro polyadenylation assay, co-immunoprecipitation, RNA-binding assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution, in vitro enzymatic assay, and binding experiments in a single study; >200 citations\",\n      \"pmids\": [\"14749727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Yeast Fip1 (ortholog of human FIP1L1) directly interacts with poly(A) polymerase (Pap1) in a 1:1 complex; it is an essential component of polyadenylation factor I (PF I); Fip1 tethers Pap1 to cleavage factor I (CF I) via direct interaction with RNA14; loss of Fip1 specifically abolishes polyadenylation (but not cleavage) in vitro.\",\n      \"method\": \"Two-hybrid assay, in vitro reconstitution (1:1 complex with Pap1), in vitro 3'-end processing assay with thermosensitive allele, co-immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution, genetic, and biochemical evidence in a single foundational study; >120 citations\",\n      \"pmids\": [\"7736590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Yeast Fip1 has distinct functional domains: amino acids 80-105 bind Pap1 and inhibit its activity (by restricting RNA access to Pap1's C-terminal RNA-binding domain); amino acids 206-220 interact with Yth1 and are required for specific polyadenylation; the C-terminus of Fip1 is required to relieve Fip1-mediated repression of Pap1.\",\n      \"method\": \"Domain deletion mutagenesis, in vitro polyadenylation assay, binding assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with in vitro functional readout, multiple domains mapped; relevant yeast ortholog\",\n      \"pmids\": [\"11238938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structure of yeast poly(A) polymerase in complex with Fip1 peptide (residues 80-105) at 2.6 Å resolution shows the Fip1 peptide binding to the outside surface of the C-terminal domain of Pap1; Fip1 is largely intrinsically disordered in solution; a lethal polymerase mutant (V498Y, C485R) that cannot bind Fip1 but retains full polymerase activity was engineered.\",\n      \"method\": \"X-ray crystallography, analytical ultracentrifugation, circular dichroism, mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation; yeast ortholog of FIP1L1\",\n      \"pmids\": [\"18537269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Yeast Fip1 contains a flexible linker region in the middle of the protein; removal or replacement of this linker impairs polyadenylation efficiency; the linker provides a platform for critical interactions with other processing machinery components, and direct tethering of Pap1 to RNA rescues polyadenylation.\",\n      \"method\": \"In vitro polyadenylation assay, fusion protein complementation in vivo, genetic assays in yeast\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro polyadenylation plus in vivo genetic rescue; yeast ortholog of FIP1L1\",\n      \"pmids\": [\"21282348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mouse Fip1 is essential for embryonic stem cell (ESC) self-renewal and somatic cell reprogramming; Fip1 promotes stem cell maintenance by activating ESC-specific alternative polyadenylation (APA) profiles through Fip1-RNA interactions and proximity between APA sites; Fip1 expression and the APA program change during ESC differentiation and are restored during reprogramming.\",\n      \"method\": \"Genetic loss-of-function (Fip1 knockout/knockdown), RNA-seq/APA profiling, reprogramming assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined cellular phenotype (loss of self-renewal), mechanism linked to APA regulation; >135 citations\",\n      \"pmids\": [\"24596251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structure of human CPSF30 ZF4-ZF5 in complex with hFip1 residues 161-200 at 1.9 Å resolution shows one hFip1 molecule binding each of ZF4 and ZF5 with a conserved interaction mode; CPSF contains two copies of hFip1; ZF4 has higher affinity (Kd = 1.8 nM); two copies of PAP are recruited by the CPSF30-hFip1 complex, both supporting polyadenylation.\",\n      \"method\": \"X-ray crystallography, mutagenesis, fluorescence polarization binding assay, in vitro polyadenylation assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis and biochemical validation in a single study\",\n      \"pmids\": [\"33122294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Yeast Fip1 anchors poly(A) polymerase Pap1 onto the CPF complex via interaction with zinc finger 4 of Yth1 (CPSF30 ortholog); NMR spectroscopy of selectively labeled Fip1 in a reconstituted 850-kDa CPF complex shows that the Fip1 IDR connecting Yth1- and Pap1-binding sites remains highly dynamic within the complex.\",\n      \"method\": \"Reconstitution of fully recombinant CPF, NMR spectroscopy, binding assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of megadalton complex with NMR structural validation; yeast ortholog\",\n      \"pmids\": [\"34593603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Human Fip1 (hFip1) acts as a multivalent scaffold within CPSF: two copies of hFip1 each bind to ZF4 and ZF5 of CPSF30 (independently redundant for PAP recruitment); hFip1 interacts with CstF77 via a short motif in its N-terminal acidic region; CstF77 competitively inhibits CPSF-dependent PAP recruitment and polyadenylation.\",\n      \"method\": \"Crystal structures of hFip1-CPSF30 and hFip1-CstF77 complexes, in vitro polyadenylation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — two crystal structures plus functional polyadenylation assays; competitive inhibition mechanism established\",\n      \"pmids\": [\"36073787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FIP1L1-PDGFRalpha activates multiple downstream signaling pathways in human hematopoietic progenitors: STAT5 and Akt activation require the FIP1L1 portion (aa 30-233), whereas p38 and ERK1/2 are activated by both full-length and truncated FIP1L1-PDGFRalpha; combined inhibition of PI3K and ERK1/2 significantly reverses FIP1L1-PDGFRalpha-induced colony formation; dominant-negative STAT5 partially inhibits colony formation.\",\n      \"method\": \"Retroviral transduction of human CD34+ progenitors, dominant-negative constructs, small-molecule pathway inhibitors, colony assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (DN-STAT5, PI3K inhibitor, ERK inhibitor, deletion mutants) in primary human cells\",\n      \"pmids\": [\"17440089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells by more intensely activating MEK1/2 and p38 MAPK than TEL-PDGFRbeta; MEK1/2 and p38 inhibitors suppress this eosinophil development; FIP1L1-PDGFRalpha augments C/EBPalpha, GATA-1, and GATA-2 expression and suppresses PU.1 transcriptional activity via Ras.\",\n      \"method\": \"Murine hematopoietic progenitor transduction, kinase inhibitors, shRNA knockdown, luciferase reporter assays, bone marrow transplantation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches identifying pathway and transcription factor mechanism; in vivo and in vitro\",\n      \"pmids\": [\"19147501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FIP1L1-PDGFRalpha and TEL-PDGFRbeta fusion proteins escape ubiquitination and proteasomal degradation (unlike wild-type activated receptors); Cbl-mediated ubiquitination is strongly reduced for the fusion proteins despite Cbl being phosphorylated; reducing SRC activity stabilizes FIP1L1-PDGFRalpha, and forced destabilization of the fusion reduces STAT5 activation and cell transformation.\",\n      \"method\": \"Pulse-chase protein stability assays, ubiquitination assays, destabilizing domain fusion constructs, patient leukocyte analysis\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (pulse-chase, ubiquitination, engineered degron) with functional consequence; replicated in patient cells\",\n      \"pmids\": [\"19644140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FIP1L1-PDGFRalpha activates JAK2, which is required for fusion kinase-induced proliferation and migration; JAK2 inhibition reduces STAT3 activation (not STAT5), and also reduces PI3K/Akt and NF-κB activity; JAK2 mediates IL-5-induced migration of FIP1L1-PDGFRalpha-positive cells.\",\n      \"method\": \"siRNA knockdown, JAK2 inhibitor AG490, signaling pathway analysis (Western blot) in EOL-1 and primary patient cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA and small molecule inhibitor with pathway readouts; single lab\",\n      \"pmids\": [\"22523564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FIP1L1-PDGFRalpha activates NF-κB via PI3K; NF-κB activity is required for eosinophil differentiation marker expression (IL-5 receptor, eosinophil peroxidase) and colony formation from transduced human CD34+ hematopoietic progenitors; bortezomib and IκB kinase inhibitor block EOL-1 cell proliferation.\",\n      \"method\": \"Lentiviral transduction of human CD34+ cells, PI3K inhibitor, dominant-negative IκB, bortezomib treatment, expression microarrays\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitor approaches in primary human cells; pathway mechanistically defined\",\n      \"pmids\": [\"22271894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SHP2 phosphatase binds directly to phospho-tyrosine 720 of FIP1L1-PDGFRalpha; this interaction is required for ERK signaling and cell transformation but not for STAT5 phosphorylation; mutation of Y720 inhibits myeloproliferation in transplanted mice and human CD34+ progenitor proliferation.\",\n      \"method\": \"Tyrosine mutagenesis, direct binding assay, SHP2 knockdown, in vivo murine bone marrow transplantation, human CD34+ progenitor assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding demonstrated, mutagenesis with in vivo and in vitro functional readout; multiple orthogonal methods\",\n      \"pmids\": [\"24618081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The F604S mutation in FIP1L1-PDGFRalpha creates a binding site for the phosphatase domain of SHP-2, reducing CBL activation and SRC-dependent destabilization, thereby strongly stabilizing the fusion protein; SRC inhibition/knockdown mimics the stabilizing effect, establishing SRC as a regulator of FIP1L1-PDGFRalpha protein stability.\",\n      \"method\": \"Pulse-chase protein stability assay, SHP-2 binding assay, SRC inhibition/knockdown, mutagenesis screen\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple complementary methods (pulse-chase, binding, SRC KD) establishing mechanism; single lab\",\n      \"pmids\": [\"25761934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The FIP1 motif in FIP1L1-RARA plays a pivotal role in homodimerization and transcriptional repressor activity of the fusion; in FIP1L1-PDGFRalpha, the C-terminal PDGFRalpha portion alone can homodimerize and constitutively activate the kinase, making FIP1L1 dispensable for kinase activation but contributing to full IL-3 independence.\",\n      \"method\": \"Deletion mutant analysis, hematopoietic cell transformation assays in BAF-B03 cells\",\n      \"journal\": \"Annals of hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — deletion series with functional readout; consistent with PMID 16690743\",\n      \"pmids\": [\"24763514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FIP1L1-PDGFRalpha cooperates with IL-5 to induce HES/CEL-like disease in mice; transplantation of FIP1L1-PDGFRalpha-positive HSCs alone produces a CML-like phenotype, but combined with IL-5 transgenic overexpression produces intense eosinophilia and multi-organ eosinophil infiltration, demonstrating that FIP1L1-PDGFRalpha is not sufficient alone and requires a second cytokine-driven event.\",\n      \"method\": \"Bone marrow transplantation in mice with IL-5 transgenic background; secondary transplantation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis experiment with clear mechanistic conclusion; >60 citations\",\n      \"pmids\": [\"16418325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FIP1L1/PDGFRalpha synergizes with SCF/c-kit signaling to promote mast cell development; SCF stimulates greater migration and Akt activation in FIP1L1/PDGFRalpha-expressing mast cells, and anti-c-kit antibody reduces but does not abolish F/P-induced intestinal mast cell infiltration in vivo.\",\n      \"method\": \"Murine bone marrow transplantation, anti-c-kit antibody neutralization, in vitro mast cell cytokine-independent proliferation and migration assays, Akt signaling analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization plus in vitro signaling; shows synergism between two kinase pathways\",\n      \"pmids\": [\"18539901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant T674I mutant, inducing apoptosis of EOL-1 cells at low nanomolar concentrations and blocking FIP1L1-PDGFRalpha phosphorylation by Western blot.\",\n      \"method\": \"Cell proliferation assay (Ba/F3 transformed cells, EOL-1), Western blot for kinase phosphorylation, apoptosis assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct kinase inhibition demonstrated with multiple cell models; >115 citations\",\n      \"pmids\": [\"16645167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FIP1L1-PDGFRalpha induces eosinophil cell proliferation through induction of c-Myc expression via ERK and JNK signaling pathways; imatinib inhibits ERK and JNK phosphorylation and decreases c-Myc protein.\",\n      \"method\": \"MEK inhibitor (U0126), JNK inhibitor (SP600125), imatinib treatment; Western blot and proliferation assays in EOL-1 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with specific small-molecule inhibitors; single lab\",\n      \"pmids\": [\"18086564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FIP1L1/PDGFRalpha (F/P) upregulates oncostatin M (OSM) expression in a STAT5-dependent manner; OSM produced by neoplastic eosinophils stimulates stromal cell proliferation and CXCL12 production, which in turn induces neoplastic eosinophil migration—establishing a paracrine loop.\",\n      \"method\": \"Lentiviral F/P transduction, doxycycline-inducible F/P expression in Ba/F3, gene expression analysis, cytokine assays, chemotaxis assays, immunohistochemistry of patient bone marrow\",\n      \"journal\": \"Allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — inducible system plus patient tissue validation; pathway mechanism established\",\n      \"pmids\": [\"23621172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FIP1 (human FIP1L1) binds to the proximal polyadenylation signal (pPAS) of NLRP3 mRNA via its arginine-rich domain and induces 3'UTR shortening of NLRP3, upregulating NLRP3 expression; FIP1 is upregulated by oxidative stress and this upregulation amplifies NLRP3-driven inflammation and fibrogenesis in kidney injury.\",\n      \"method\": \"RNA immunoprecipitation, shRNA knockdown, in vivo UUO/IRI kidney injury models, NLRP3 3'UTR reporter assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA binding demonstrated (RIP), KD with in vivo phenotypic rescue; mechanism linked to APA regulation\",\n      \"pmids\": [\"34011928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Human Fip1 (hFip1) interacts specifically with U-rich upstream elements of the HPV-16 early polyadenylation signal region, enhancing polyadenylation at the early poly(A) site; deletion of this U-rich element reduces early poly(A) site utilization and increases late mRNA production.\",\n      \"method\": \"RNA-protein binding assay, deletion mutagenesis, polyadenylation reporter assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA-protein binding plus functional reporter assay; consistent with known hFip1 U-rich binding mechanism\",\n      \"pmids\": [\"15767428\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FIP1L1 encodes two functionally distinct proteins: (1) as a core subunit of the CPSF mRNA 3'-end processing complex, hFip1 serves as a multivalent intrinsically disordered scaffold that binds U-rich RNA elements via its arginine-rich motif, recruits poly(A) polymerase (PAP) by tethering it to CPSF30 (ZF4/5) and stimulates PAP activity, interacts with CstF77 which competitively inhibits PAP recruitment, and regulates alternative polyadenylation essential for stem cell self-renewal; (2) when fused to PDGFRalpha by a cryptic 4q12 chromosomal deletion, the FIP1L1 portion is dispensable for constitutive kinase activation (which instead requires disruption of the PDGFRalpha juxtamembrane autoinhibitory domain), but the fusion oncoprotein—which escapes ubiquitination and degradation—drives myeloproliferation by activating STAT5, PI3K/Akt, ERK, p38, JAK2, NF-κB, and SHP2/ERK pathways, imposes eosinophil lineage commitment through MEK1/2-p38-C/EBPalpha/GATA axis, and is potently inhibited by imatinib (with T674I and D842V mutations conferring resistance).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FIP1L1 encodes hFip1, an intrinsically disordered scaffold subunit of the cleavage and polyadenylation specificity factor (CPSF) complex that is essential for mRNA 3'-end processing and alternative polyadenylation (APA). Two copies of hFip1 bind CPSF30 zinc fingers ZF4 and ZF5 to recruit poly(A) polymerase (PAP) via its arginine-rich RNA-binding motif that preferentially recognizes U-rich elements, while CstF77 competitively inhibits PAP recruitment through a distinct hFip1 N-terminal interaction, providing a regulatory switch for polyadenylation [PMID:14749727, PMID:33122294, PMID:36073787]. hFip1-directed APA is required for embryonic stem cell self-renewal and somatic cell reprogramming, and regulates inflammatory gene expression through 3'UTR shortening of targets such as NLRP3 [PMID:24596251, PMID:34011928]. A cryptic interstitial deletion on chromosome 4q12 fuses FIP1L1 to PDGFRα, generating a constitutively active tyrosine kinase—driven by loss of the PDGFRα juxtamembrane autoinhibitory domain rather than by the FIP1L1 moiety—that activates STAT5, PI3K/Akt, ERK, p38, JAK2, NF-κB, and SHP2 pathways to cause imatinib-sensitive myeloproliferative neoplasm with eosinophilia [PMID:12660384, PMID:16690743, PMID:17440089, PMID:24618081].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"The founding discovery that yeast Fip1 is an essential polyadenylation factor that directly tethers poly(A) polymerase to the cleavage machinery established FIP1 as a core 3'-end processing component, resolving how PAP is recruited to pre-mRNA substrates.\",\n      \"evidence\": \"Two-hybrid, reconstitution of 1:1 Fip1–Pap1 complex, in vitro processing assay with thermosensitive allele in S. cerevisiae\",\n      \"pmids\": [\"7736590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human ortholog not yet characterized\", \"RNA-binding specificity of Fip1 unknown\", \"Structural basis of Fip1–Pap1 interaction unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Domain mapping of yeast Fip1 revealed a dual-function architecture: one region binds and inhibits Pap1 while another contacts Yth1 (CPSF30 ortholog), explaining how Fip1 both represses nonspecific polyadenylation and enables site-specific poly(A) addition.\",\n      \"evidence\": \"Deletion mutagenesis with in vitro polyadenylation and binding assays in yeast\",\n      \"pmids\": [\"11238938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Fip1-mediated repression is relieved in the full complex unknown\", \"No structural data on Fip1–Yth1 interface\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of the FIP1L1-PDGFRα fusion as a constitutively activated kinase caused by a 4q12 interstitial deletion established the molecular basis of imatinib-responsive hypereosinophilic syndrome, and the T674I gatekeeper mutation explained clinical imatinib resistance.\",\n      \"evidence\": \"Cell transformation assays, kinase inhibition (IC50 3.2 nM), sequencing of relapsed patient; confirmed in murine BM transplant model with PKC412 rescue\",\n      \"pmids\": [\"12660384\", \"12781364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which portion of the fusion drives activation unclear\", \"Downstream effector pathways not mapped\", \"Mechanism of eosinophil lineage specificity unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Biochemical characterization of human hFip1 demonstrated it is a CPSF subunit with an arginine-rich motif that binds U-rich RNA and stimulates PAP activity, establishing conservation of the yeast Fip1 mechanism in mammals.\",\n      \"evidence\": \"Recombinant protein reconstitution, in vitro polyadenylation, co-IP, RNA-binding assay\",\n      \"pmids\": [\"14749727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of hFip1 within CPSF unknown\", \"Structural basis of hFip1–CPSF30 interaction unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mutagenesis of FIP1L1-PDGFRα demonstrated that constitutive kinase activation requires disruption of the PDGFRα juxtamembrane autoinhibitory domain, while the FIP1L1 moiety is entirely dispensable, resolving a key question about the activation mechanism.\",\n      \"evidence\": \"Deletion mutagenesis, in vitro kinase assays, Ba/F3 transformation, murine models\",\n      \"pmids\": [\"16690743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of FIP1L1 portion in signaling specificity or protein stability not addressed\", \"Mechanism of eosinophil commitment still unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapping of FIP1L1-PDGFRα downstream signaling in human CD34+ progenitors revealed that STAT5 and Akt activation require the FIP1L1 N-terminal portion (aa 30–233) while ERK and p38 do not, showing the fusion partners differentially route oncogenic signals.\",\n      \"evidence\": \"Retroviral transduction of human CD34+ cells, dominant-negative STAT5, PI3K/ERK inhibitors, colony assays\",\n      \"pmids\": [\"17440089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of FIP1L1 requirement for STAT5/Akt signaling unclear\", \"In vivo validation in patient-derived cells limited\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Crystal structure of the yeast Fip1 peptide–Pap1 complex revealed that Fip1 is intrinsically disordered and binds the outer surface of Pap1's C-terminal domain, providing the first atomic view of how this scaffold restricts polymerase activity.\",\n      \"evidence\": \"X-ray crystallography (2.6 Å), analytical ultracentrifugation, CD, lethal Pap1 mutants\",\n      \"pmids\": [\"18537269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length Fip1 structure unavailable\", \"Human hFip1–PAP complex structure unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Two studies established that FIP1L1-PDGFRα escapes Cbl-mediated ubiquitination (explaining its stability compared to wild-type receptors) and imposes eosinophil lineage commitment through MEK1/2–p38–C/EBPα/GATA signaling, connecting protein turnover and lineage specification to disease phenotype.\",\n      \"evidence\": \"Pulse-chase stability assays, ubiquitination assays, destabilizing domain fusions; murine progenitor transduction with kinase inhibitors and shRNA, BM transplantation\",\n      \"pmids\": [\"19644140\", \"19147501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How fusion evades Cbl ubiquitination structurally is unknown\", \"Whether lineage commitment mechanism operates identically in human patients unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"hFip1 was shown to be essential for embryonic stem cell self-renewal through regulation of ESC-specific alternative polyadenylation programs, establishing FIP1L1 as a master regulator of APA in cell fate decisions beyond constitutive 3'-end processing.\",\n      \"evidence\": \"Fip1 knockout/knockdown in mouse ESCs, RNA-seq/APA profiling, reprogramming assays\",\n      \"pmids\": [\"24596251\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Fip1 selects specific APA sites over others not resolved\", \"Whether hFip1 levels regulate APA in adult somatic tissues unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of SHP2 binding to phospho-Y720 of FIP1L1-PDGFRα as required for ERK signaling and transformation but dispensable for STAT5 activation revealed a branchpoint separating two major oncogenic pathways downstream of the fusion.\",\n      \"evidence\": \"Y720 mutagenesis, direct binding assay, SHP2 knockdown, murine BM transplantation, human CD34+ assays\",\n      \"pmids\": [\"24618081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other phosphotyrosine docking sites on the fusion not systematically mapped\", \"Whether SHP2 inhibitors have therapeutic utility not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Crystal structures of hFip1 bound to CPSF30 ZF4 and ZF5 revealed that CPSF contains two copies of hFip1, each recruiting one PAP molecule, establishing the stoichiometric and structural basis for multivalent PAP recruitment within the mammalian polyadenylation machinery.\",\n      \"evidence\": \"X-ray crystallography (1.9 Å), fluorescence polarization binding (Kd 1.8 nM for ZF4), mutagenesis, in vitro polyadenylation\",\n      \"pmids\": [\"33122294\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of having two PAP copies versus one not determined\", \"Full CPSF holoenzyme structure with hFip1 not available\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that CstF77 binds hFip1's N-terminal region and competitively inhibits PAP recruitment revealed a built-in regulatory switch within CPSF that controls the transition from cleavage to polyadenylation.\",\n      \"evidence\": \"Crystal structures of hFip1–CstF77 complex, in vitro polyadenylation assays showing competitive inhibition\",\n      \"pmids\": [\"36073787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CstF77 release is triggered during the cleavage-to-polyadenylation transition in vivo unknown\", \"Regulation of this switch in APA site selection not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of hFip1's RNA-binding specificity for U-rich elements, the mechanism by which hFip1 selects between proximal and distal polyadenylation sites in vivo, and whether the two copies of hFip1 within CPSF serve functionally distinct roles remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of hFip1 arginine-rich domain bound to RNA\", \"No genome-wide dissection of individual hFip1 copy contributions\", \"How hFip1-driven APA interfaces with transcription elongation rate is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [3, 4, 25, 26]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 9, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0043226\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [3, 4, 5, 8, 9, 11, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 12, 13, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2, 12, 13, 14]}\n    ],\n    \"complexes\": [\n      \"CPSF (cleavage and polyadenylation specificity factor)\"\n    ],\n    \"partners\": [\n      \"CPSF1\",\n      \"CPSF4\",\n      \"PAPOLA\",\n      \"CSTF3\",\n      \"PDGFRA\",\n      \"SHP2\",\n      \"CBL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}